Boehringer Ingelheim Archives

News and Trends 8 Jun 2016

12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting

Pharma and Biotech from every corner flocked to Chicago for the beginning of June. Why? It’s where one of the biggest oncology events happens – the ASCO Annual Meeting 2016. Shortly after the AACR annual meeting (with presentations from several European Biotechs), it’s time for the ASCO annual meeting. Hosted by the American Society of Clinical […]

June 8, 2016 - 7 minutesmins - By Denise Neves Gameiro

oxford biotherapeutics drug cancer boehringer

News and Trends 18 Apr 2016

UK Drug Discovery sells Cancer Target to German Pharma

Boehringer Ingelheim has bought exclusive rights to an oncology target discovered by Oxford BioTherapeutics and its proteomic database. Oxford BioTherapeutics is a Biotech in Milton Park (near Oxford, UK), developing immunotherapies for cancer with antibody-drug conjugates (ADC) – a strategy to combine the specificity of antibodies to a toxic agent that can be delivered to a cancerous cell. […]

April 18, 2016 - 2 minutesmins - By Denise Neves Gameiro

migraine biotech cgrps heptares review neurology

News and Trends 17 Mar 2016

A Relief for Migraines at last? The Biotech race for the Ultimate Cure

A Migraine is more than just a headache; it is a neurological disorder affecting a staggering 10% of the worldwide population. So where are we on fighting a viable therapy – and who is working on Migraines? People of all ages are at risk of migraine, with women being three times more likely to suffer from […]

March 17, 2016 - 4 minutesmins - By Ekaterina Perets

boehringer ingelheim abbvie psoriasis interleukin23 bi655066 bi655066 Crohns asthma psoriatic arthritis

News and Trends 9 Mar 2016

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including psoriasis and Crohn’s disease. Therapies for immune diseases continue to attract Pharma’s attention (and money). This time, two of 25 leading Big Pharma worldwide, AbbVie and Boehringer Ingelheim, have partnered to develop 2 different immunological candidates. […]

March 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

biosimilar war neulasta herceptin avastin rituxan1

News and Trends 25 Nov 2015

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Novartis is hitting back in the Biosimilar battleground: now Neulasta, the white blood cell booster for Cancer, is the latest of Amgen’s victims… Neulasta (pegfilgrastim) has been submitted through Novartis’ subsidiary, Sandoz. As a recombinant human granulocyte colony-stimulating factor (G-CSF), pegfilgrastim looks to stimulate the immune system and boost the white cell count. Neulasta is […]

November 25, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 15 Oct 2015

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Ablynx – the Belgian nanobody biotech (which uses monoclonal antibodies of Alpacas), has now achieved it’s first pre-clinical milestone in its immuno-oncology partnership with MSD (Merck & Co). Now Ablynx has achieved proof of concept for one of the 17 Nanobodies being studied. Ablynx has therefore received the first €3.5M in milestone payments from MSD […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 1 Oct 2015

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Paris based Sofinnova continues to invest in the Alzheimer’s fight, with a €27.5M pot given to Swiss Asceneuron (originally a spin-off from Merck-Serono). Sofinnova therefore joins other investors such as JJDC in the new and optimistic biotech wave of therapies for neurodegenerative diseases like Alzheimer’s and progressive supranuclear palsy (PSP). The last decade has been fairly […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 24 Sep 2015

Crowdsourcing for Innovation: BioMed X has just the right Recipe

Ever heard of BioMed X? If you are curious about innovation crowdsourcing, you should definitely check them out. BioMed X is one of the first companies to use crowdsourcing to discover new innovation in the life sciences, through which a biotech team has been assembled and financed to develop a new treatment for COPD. Chronic obstructive pulmonary […]

September 24, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 1 Sep 2015

Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

A new research competition is born. The European Society of Cardiology and Boehringer Ingelheim will award €400k to four research projects treating cardiovascular diseases. Big Pharmas like to give a push to aspiring research projects within their field. GSK is a key partner of the world’s largest life science startup accelerator, namely OneStart. Sanofi is engaged […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 30 Jul 2015

Boehringer Ingelheim signs €661M deal for New Lung Cancer Treatment

Boehringer Ingelheim puts a new pillar in its oncology pipeline. The German giant acquired a Phase II compound for the treatment of lung cancer from the Korean pharma company Hamni. Non-small cell lung cancer makes up about 90% of all lung cancers. A targeted therapy includes the inhibition of the epidermal growth factor receptor (EGFR), […]

July 30, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Jul 2015

Ablynx and MSD upgrade their €1.7Bn deal to gigantic €5.7Bn

Using camel antibodies as drugs, sounds crazy? Belgian Ablynx is exactly doing that and has been very successful so far. It’s now moving to the next step. It already signed a €1.7Bn deal with Merck & Co. in February 2014 and now upgrades it to a gigantic €5.7Bn! Ablynx is a biotech company developing Nanobodies for immune-oncology […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 19 May 2015

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Does NASH mean anything to you? You should be vigilant about this market as it could be the source of next major blockbusters. This new and latest acquisition by Boehringer, is yet another sign of the growing interest for NASH treatments, already chased by companies such as Intercept, Genfit or Gilead. NASH, or non-alcoholic steatohepatitis, is regarded as […]

May 19, 2015 - 4 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Boehringer Ingelheim

12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting

UK Drug Discovery sells Cancer Target to German Pharma

A Relief for Migraines at last? The Biotech race for the Ultimate Cure

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Crowdsourcing for Innovation: BioMed X has just the right Recipe

Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

Boehringer Ingelheim signs €661M deal for New Lung Cancer Treatment

Ablynx and MSD upgrade their €1.7Bn deal to gigantic €5.7Bn

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!